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Abstract 162 
Refractive errors, including myopia, are the most frequent eye disorders worldwide and an increasingly 163 
common cause of blindness. Through a genome-wide association meta-analysis in 160,420 participants of 164 
mixed ancestry from CREAM and 23andMe and replication in 95,505 participants from the UK Biobank, 165 
we increased the number of significant independent signals from 37 to 161 and found a high genetic 166 
correlation between Europeans and Asians (>0.78). Enrichment analysis identified retinal cell physiology 167 
and light processing as the most prominent mechanisms. Expression experiments and comprehensive in 168 
silico analyses of the novel genes showed functional contribution of all cell types in the neurosensory 169 
retina (GNB3, DRD1, AKAP6, ZEB2, TFAP2B, CA8, EDN2), the retinal pigment epithelium (EFEMP1, 170 
ANO2), vascular endothelium (CD34, FLT1), and extracellular matrix (VIPR2, ANTXR2, TCF7L2, 171 
COL10A1) to refractive error development. The newly identified genes also elicited novel mechanisms 172 
such as rod as well as cone bipolar synaptic neurotransmission (rod: CLU; cone: GNB3), anterior segment 173 
morphology (TCF7L2, VIPR2, MAF), and angiogenesis (FLT1). Twenty eight SNPs resided in or near 174 
DNA structures transcribing small RNAs (non-coding, tRNAs, snoRNas, rRNAs, miRNA), suggesting a 175 
role for post-transcriptional regulation. Our results support the notion that refractive errors are caused by a 176 
light-dependent retina-to-sclera signaling cascade, and delineate potential molecular drivers defining the 177 
pathobiology of refractive errors and myopia. 178 
 179 
  180 
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Introduction 181 
Refractive errors are common optical aberrations determined by mismatches in the focusing power of the 182 
cornea, lens and axial length of the eye. Their distribution is rapidly shifting towards myopia, or 183 
nearsightedness, all over the world. The myopia boom is particularly prominent in urban East Asia where 184 
up to 95% of twenty-year-olds in cities such as Seoul and Singapore have this refractive error1-4. Myopia 185 
prevalence is also rising throughout Western Europe and the USA, affecting ~50% of young adults in 186 
these regions5,6. While refractive errors can be optically corrected, even at moderate values they carry a 187 
significant risk of ocular complications with a high economic burden7-9. One in three individuals with 188 
high myopia (-6 diopters or worse) will develop irreversible visual impairment or blindness, mostly due 189 
to myopic macular degeneration, retinal detachment, or glaucoma10,11. At the other extreme, high 190 
hyperopia predisposes to strabismus, amblyopia and angle-closure glaucoma10,12.  191 
 Refractive errors result from a complex interplay of lifestyle and genetic factors. Most established 192 
lifestyle factors for myopia are high education, lack of outdoor exposure, and excessive near work3. 193 
Recent research has identified many genetic variants for refractive errors, myopia, and axial length13-25. 194 
Two large studies, the international Consortium for Refractive Error and Myopia (CREAM)26 and the 195 
personal genomics company 23andMe, Inc.17,27 have provided the most comprehensive results. Despite 196 
differences in design and methodology, 37 associated genetic loci were identified in common, and most 197 
strikingly, there was a near-linear relationship in genetic effect sizes of the associated variants28. 198 
  Given that only 3.6% of the variance of the refractive error trait was explained by the identified 199 
genetic variants26, we presumed a high missing heritability. We therefore combined CREAM and 200 
23andMe, and expanded the study sample to 160,420 individuals from a mixed ancestry population with 201 
quantitative information on refraction for a genome-wide association (GWA) meta-analysis. Significant 202 
variants were tested for replication in an independent cohort consisting of 95,505 individuals from the UK 203 
Biobank. We conducted systematic comparisons to assess differences in genetic inheritance and 204 
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distribution of risk variants between Europeans and Asians. Polygenic risk analyses were performed to 205 
evaluate the contribution of the identified variants to the risk of myopia and hyperopia. Finally, we 206 
integrated expression data and bioinformatics on the identified genes to gain insight into the possible 207 
mechanisms underlying the genetic associations.  208 
   209 
  210 
  211 
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RESULTS 212 
Susceptibility loci for refractive error  213 
We performed a GWAS meta-analysis on adult refractive error using summary statistics from 37 studies 214 
from the Consortium for Refractive Error and Myopia (CREAM) and two cohorts from the personal 215 
genomics company 23andMe (Supplementary Figure 1). Analyses were based on ~11 million genetic 216 
variants (SNPs, insertions and deletions) genotyped or imputed to 1000 Genomes Project Phase I 217 
reference panel (version 3, March 2012 release29) that passed extensive quality control (Supplementary 218 
Figures 2-5, Supplementary Table 1a) and were represented by at least half of the entire study population 219 
and by > 13 cohorts from CREAM and both cohorts from 23andMe. 220 
 Meta-analyses were conducted in three stages. Stage 1 focused on CREAM and included a fixed 221 
effects inverse variance-weighted meta-analysis on 44,192 individuals of European descent (CREAM-222 
EUR) and 11,935 participants of East or South Asian ancestry (CREAM-ASN) using untransformed 223 
spherical equivalent (SphE) as the dependent variable representing refractive error (Supplementary Table 224 
1b). 1,063 variants clustering in 24 loci (Supplementary Excel File 1) were genome-wide significant (P 5 225 
x 10-8). Stage 2 consisted of a fixed effects inversed variance-weighted meta-analysis of the two European 226 
23andMe cohorts (N23andMe_V2= 12,128; N23andMe_V3 = 92,165) using age of diagnosis of myopia (AODM) as 227 
outcome27. A total of 5,205 genome-wide significant variants clustered in 112 loci (Supplementary Excel 228 
File 1). All 25 loci identified at Stage 1 replicated in Stage 2 (pBonferroni 2.00 x 10-3). Vice versa, 29 229 
(26%) of the loci identified at Stage 2 replicated in Stage 1 (pBonferroni 4.46 x 10-4), an expected 230 
proportion given the lower statistical power in CREAM. Stage 3 was the joint meta-analysis of Stage 1 231 
and Stage 2. As CREAM and 23andMe applied different phenotype measures, we used signed Z-scores as 232 
the mean per-allele effect size and assigned equal weights to CREAM and 23andMe. We identified 7,967 233 
genome-wide significant genetic variants clustering in 140 loci (Figure 1a; Supplementary Figure 5-6, 234 
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Supplementary Excel File 1 – 3, Supplementary PDF File 1 and 2) of which 104 were novel. All 37 loci 235 
that were found previously by CREAM and 23andMe using genotype data imputed to the HapMap II 236 
reference panel were replicated (pBonferroni 1.85 x 10-3), and 36 of the 37 were genome-wide significant 237 
(Supplementary Table 2)26,27. We applied genomic control at each stage and checked for population 238 
stratification using LD score regression30 (Supplementary Table 3). At Stage 1 and 2, population 239 
stratification was unlikely as inflation factors (λGC ) were < 1.1 (Supplementary Figure 7), and LD score 240 
regression intercepts (LDSCintercept) ranged from 0.892 to 1.023 (Supplementary Figure 8). At Stage 3, we 241 
observed an inflation of the median test statistic (λGC=1.129; Supplementary Figure 6), probably due to 242 
true polygenicity rather than bias (i.e. population stratification or cryptic relatedness)31. The mixed 243 
ancestry did not allow for calculation of LDSCintercept. 244 
 To detect the presence of multiple independent signals at the discovered loci, a stepwise 245 
conditional analysis was performed with GCTA-COJO32 on meta-analysis summary statistics from all 246 
European cohorts (N=148,485) using the Rotterdam Study I-III (RS I-III) as a reference panel for LD 247 
structure (NRSI-III = 10,775). This analysis yielded 27 additional independent variants, resulting in a total of 248 
167 loci (Supplementary Excel File 1). The lead variants at the newly-discovered loci were mainly of 249 
lower minor allele frequencies (MAFs) than those reported in previous refractive error GWAS studies 250 
with lower samples, reflecting the increased statistical power of the current analysis (Figure 1b). 251 
We advanced these loci for replication analysis in a GWAS of refractive error carried out by the 252 
UK Eye & Vision (UKEV) Consortium in 95,505 participants of European ancestry from the UK 253 
BioBank. 3316 variants were not present in UKEV, and were represented by a surrogate variant in high 254 
LD (r2 >0.8 LD; Supplementary Excel File 1). Six out of the 167 variants were not considered for 255 
replication analysis: one variant (rs188159083) was not present on the array nor a surrogate was available 256 
in UKEV and five variants showed evidence of departure from HWE (HWE exact test P < 3.0 x 10-4, 257 
where 3.0 x 10-4 =0.05/167). One of these five variants (rs3138141, RDH5) was identified previously and 258 
therefore still considered as a refractive error risk variant26,27. The remaining 161 genetic variants were 259 
tested for replication. 86% (138/161) of the candidate variants replicated significantly: 104 (65%) 260 
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replicated surpassing genome wide significance; 34 replicated surpassing Bonferroni correction (P < 3.0 x 261 
10-4; 21.1%); and, 12 showed nominal evidence for replication (0.05 < P < 3.0 x 10-4; 7.5%). Of the total, 262 
only 11 (7%) did not replicate (Table 1 and Supplementary Excel File 1). 263 
 As CREAM and 23andMe employed different phenotypic outcomes, we evaluated consistency of 264 
genotypic effects by comparing marker-wise additive genetic effect sizes (in units diopters per copy of the 265 
risk allele) for SphE from CREAM-EUR against those (in units log(HR) per copy of the risk allele) for 266 
AODM from 23andMe. All variants strongly associated with either outcome (P < 0.001), were 267 
concordant in direction-of-effect, and had highly correlated effect sizes (Figure 2 a,b; Supplementary 268 
Figure 9). For these variants, a 10% decrease in the log(HR) for AODM, indicating an earlier age-at-269 
myopia onset, was associated with a decrease of 0.15 diopters in SphE. A quantitative analysis for all 270 
common SNPs (MAF > 0.01; HapMap3) using LD score regression yielded a genetic correlation of 0.93 271 
(95% CI 0.86 to 0.99; P = 2.1 x 10-159), confirming that effect sizes for both phenotypic outcomes were 272 
closely related.  273 
 274 
Gene annotation of susceptibility loci 275 
We annotated all genetic variants with wANNOVAR using the University of California Santa Cruz 276 
(UCSC) Known Gene database34,35. The identified 139 genetic loci were annotated to 208 genetic 277 
structures (i.e. genes and known transcribed RNA genes, Table 1, Supplementary Excel file 1, Online 278 
Methods). The physical positions of the lead genetic variants relative to protein-coding genes are shown 279 
in Figure 1c. 86% of the identified variants were either intragenic or less than 50 kb from the 5’or 3’ end 280 
of the transcription start site. We found seven exonic variants (Supplementary Table 4) of which two had 281 
MAF ≤ 0.05: rs5442 (GNB3) and rs17400325 (PDE11A). The index SNP in the GNB3 locus with MAF 282 
0.05 in Europeans is a highly conserved missense variant (G272S) predicted to be damaging by 283 
PolyPhen-236 and SIFT37. PDE11A is presumed to play a role in tumorigenesis, brain function, and 284 
inflammation38. The index SNP in the PDE11A locus with MAF 0.03 in Europeans is also a highly 285 
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conserved missense variant (Y727C); this variant was predicted to be damaging by PolyPhen36, SIFT39 286 
and align GVGD40,41.The other exonic variants, rs1064583 (COL10A1), rs807037 (KAZALD1), rs1550094 287 
(PRSS56), rs35337422 (RD3L) and rs6420484 (TSPAN10), were not predicted to be damaging. 288 
 The most significant variant (Stage 3; rs12193446, P = 4.21 x 10-84) resides on chromosome 6 289 
within a non-coding RNA, BC035400, in an intron of the LAMA2 gene. This locus had been identified 290 
previously, but our current fine mapping redefined the most associated variant. The function and potential 291 
downstream target sites for BC035400 are currently unknown. The previously most strongly associated 292 
variant, rs524952 on chromosome 15 near GJD2, was the second most significant variant (P = 2.28 x 10-293 
65).  294 
Post-GWAS analyses identify 22 additional novel candidate loci 295 
We performed two gene-based tests, fastBAT42 and EUGENE43, and applied a functional enrichment 296 
approach using fgwas44 (Online Methods). Fgwas incorporates functional annotation (eg. DNase I 297 
hypersensitive sites in various tissues and 3’UTR regions) to reweight data from GWAS, and uses a 298 
Bayesian model to calculate a posterior probability of association. With fastBAT, we identified 13 genes 299 
at P value < 2.0 x 10-6, one of which (CHD7) had been identified previously26,27. Using EUGENE, we 300 
found 7 genes at P value < 2.0 x 10-6 after incorporation of blood eQTLs. With fgwas, we identified 6 301 
loci, which could be annotated to 9 genes, at posterior probability >0.9. Two genes (HMGN4 and TLX1) 302 
showed significant associations in two or more approaches. Taken together, these post-GWAS approaches 303 
resulted in a total of 22 additional candidate loci for refractive error, annotated to 25 genes 304 
(Supplementary Table 5). This increases the overall number of significant genetic associations to 161 305 
candidate loci. 306 
 307 
 308 
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Polygenic risk scores 309 
We calculated polygenic risk scores (PGRS)45 per individual at various P value thresholds (Online 310 
Methods) for Rotterdam Study I-III (RS I-III; N=10,792) after recalculating P values and Z-scores of 311 
variants from Stage 3 excluding RS I-III. We found the highest fraction of phenotypic variance (7.8%) 312 
explained with 7,307 variants at P value threshold 0.005 (Supplementary Table 6). A PGRS based on 313 
these variants distinguished well between individuals with hyperopia and myopia at the lower and higher 314 
deciles (Figure 3); those in the highest decile had a 40-fold increased risk of myopia. When the PGRS 315 
was stratified for the median age (< 63 or > 63+ yrs), we found a significant difference in the variance 316 
explained (<63 yrs 8.9%; 63+ yrs 7.4%; P value 0.0038). The variance explained by PGRS was not 317 
significantly different between males and females (8.3% vs 7.5%; P value 0.13). The predictive value 318 
(area under the receiver operating characteristic curve, AUC) of the PGRS for myopia versus hyperopia 319 
adjusted for age and gender was 0.77 (95% CI = 0.75–0.79), a 10% increase compared to previous 320 
estimations46.  321 
Trans-ethnic comparison of genotypic effects 322 
To explore potential ancestry differences in the identified refractive error loci, we calculated the 323 
heritability explained by common genetic variants (SNP-h2) for Europeans and Asians using LD score 324 
regression47. SNP-h2 was 0.214 (95% CI 0.185 to 0.243) and 0.172 (95% CI 0.154 to 0.190) in the 325 
European samples (CREAM-EUR and 23andMe), while it was only 0.053 (95% CI -0.025 to 0.131) in 326 
the Asian sample (CREAM-EAS). Next, we estimated the genetic correlation between Europeans and 327 
Asians by comparing variant effect size for common variants using the novel statistical program 328 
Popcorn48. Popcorn takes summary GWAS statistics from two populations and LD information from 329 
ancestry-matched reference panels, and computes genetic correlations by implementing a weighted 330 
likelihood function that accounts for the inflation of Z scores due to LD (Online Methods). Two genetic 331 
correlation metrics were calculated (Table 2); first, a genetic effect correlation (ρge) that quantifies the 332 
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correlation in SNP effect sizes between Europeans and Asians without taking into account ancestry-333 
related differences in allele frequency; and second, a genetic impact correlation (ρgi) that estimates the 334 
correlation in variance-normalized SNP effect sizes between the two ancestry groups. Estimates of the 335 
genetic effect correlation ρge were high between Europeans and Asians, but significantly different from 1 336 
(0.79 and 0.80 respectively at P <1.9 x 10-6; Table 2), indicating a clear genetic overlap but a difference in 337 
per allele effect size. Estimates of the genetic impact correlation ρgi were similarly high (> 0.8), but not 338 
significantly different from 1 for the correlation between CREAM-EUR and CREAM-ASN (P = 0.065), 339 
indicating that the genetic impact of these alleles may still be similar.  340 
 341 
In silico pathway analysis 342 
We used an array of bioinformatics tools to investigate potential functions and pathways of the associated 343 
genes. We first employed DEPICT49 to perform a gene set enrichment analysis, a tissue type enrichment, 344 
and a gene prioritization analysis, on all variants with P value < 1.00 x 10-5 from Stage 3. The gene set 345 
enrichment analysis resulted in 66 reconstituted gene sets, of which 55 (83%) were eye-related. To reduce 346 
redundancies between pathways, we clustered the significant pathways into 13 meta gene sets (false 347 
discovery rate (FDR) < 5% and a P value < 0.05) (Supplementary Methods 1, Figure 4, Supplementary 348 
Excel File 4). The most significant gene set was the ‘abnormal photoreceptor inner segment morphology’ 349 
(MP:0003730; P value = 1.79 x 10-7). The eye-related meta gene sets consisted of the ‘thin retinal outer 350 
nuclear layer’ (MP:0008515; 27 (55%) gene sets), ‘detection of light stimulus’ (GO:0009583; 13 (24%) 351 
gene sets), ‘nonmotile primary cilium’ (GO:0031513; 4 (6%) gene sets), and ‘abnormal anterior eye 352 
segment morphology’ (MP:0005193; 4 (6%) gene sets). The first three meta gene sets had a Pearson’s 353 
correlation > 0.6. Interestingly, RGR, RP1L1, RORB and GNB3 were present in all of these meta gene 354 
sets. Retina was the most significant tissue of expression according to the tissue enrichment analysis (P 355 
value = 1.11 x 10-4, FDR <0.01). From the gene prioritization according to DEPICT, 7 genes were 356 
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highlighted as the most likely causal genes at P value < 7.62 x 10-6 and FDR <0.05: ANO2, RP1L1, 357 
GNB3, EDN2, RORB and CABP4.  358 
 Next, we performed a canonical pathway analysis on all genes annotated to the variants of Stage 359 
3 using Ingenuity Pathway Analysis (IPA; http://www.ingenuity.com/index.html). All genes were run 360 
against the IPA database incorporating functional biological evidence on genomic and proteomic 361 
expression based on regulation or binding studies. IPA identified “Glutamate Receptor Signaling” with 362 
central player Nf-kB gene as the most significant pathway after correction for multiple testing (ratio of the 363 
number of molecules 8.8% and Fisher's Exact test P value = 1.56 x 10-4; Figure 5, Supplementary Figure 364 
10).  365 
 366 
From disease associated loci to biological mechanisms 367 
We adapted the scoring scheme designed by Fritsche et al.50 to highlight genes for which there is 368 
biological plausibility for a role in eye growth. We used 10 equally rated categories (maximum score 10; 369 
genes with score ≥ 5 Table 3; all genes Supplementary Excel File 5; Online Methods, Supplementary 370 
Methods 1): internal replication of index genetic variants in the individual cohort GWAS (CREAM-ASN, 371 
CREAM-EUR and 23andMe), evidence for an eQTL effect in at least four tissue or cell types, annotation 372 
to altered genomic function, ocular phenotype in humans and in mice, expression in human adult and fetal 373 
ocular tissue, the presence of genes in the gene set enrichment, the presence of genes in the prioritization 374 
analysis of DEPICT, and the presence of genes in the top 5 canonical pathway analysis of IPA. Sixty-five 375 
index variants replicated in two or more individual cohorts; we found evidence for seven genetic variants 376 
with eQTL effects in multiple tissue types; nine exonic variants, of which seven predicted protein-377 
alterations (Supplementary Table 4); 27 RNA genes, six located in the 3’ or 5’UTR (Supplementary Table 378 
7, Supplementary Figure 11), 84 genes resulting in an ocular phenotype in humans (Supplementary Excel 379 
File 6) and 28 in mice (Supplementary Excel File 7); 169/212 (79%) genes expressed in human ocular 380 
tissue (Supplementary Methods 1, Supplementary Excel File 8); 42 genes identified by DEPICT at P 381 
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value < 5.4 x 10-4 and FDR < 0.05 and 45 genes contributed to the most significant canonical pathways of 382 
IPA. Notably, 48 of the associated genes encode known drug targets (Supplementary Excel File 9). 383 
  The gene with the highest biological plausibility score (score = 8) was GNB3, a highly conserved 384 
gene encoding a guanine nucleotide-binding protein expressed in rod and cone photoreceptors and ON-385 
bipolar cells51. GNB3 participates in signal transduction through G-protein coupled receptors and 386 
enhances the temporal accuracy of phototransduction and ON-center signaling in the retina51. As 387 
described above, the index SNP harbors a missense variant associated with refractive errors. Non-388 
synonymous mutations within GNB3 are known to cause syndromic congenital stationary night 389 
blindness52 in humans, progressive retinopathy and globe enlargement in chickens51, and abnormal 390 
development of the photoreceptor-bipolar synapse in knock-out mice53,54.  391 
Other genes highly ranked (score = 7) include CYP26A1, GRIA4, RDH5, RORB and RGR, all 392 
previously associated with refractive error, and one newly identified gene: EFEMP1. EFEMP1 encodes a 393 
member of the fibulin family of extracellular matrix glycoproteins, and is found pan-ocularly including in 394 
the inner nuclear layer and Bruch’s membrane. Mutations in this gene lead to specific macular 395 
dystrophies55, while variants have also been shown to co-segregate with primary open-angle glaucoma56 396 
and associate with optic disc cup area57.  397 
 Several other genes from our analysis are noteworthy for their function. CABP4, a calcium 398 
binding protein expressed in cone and rod photoreceptor cells, mediates Ca2+ influx and glutamate release 399 
in the photoreceptor-bipolar synapse58. Mutations in this gene have been described in congenital cone-rod 400 
synaptic disorder59, a retinal dystrophy associated with nystagmus, photophobia, and, remarkably, high 401 
hyperopia. KCNMA1 encodes pore forming alpha subunits of Ca2+-activated K+ (BK) channels. These 402 
channels regulate synaptic transmission exclusively in the rod pathway60. A striking function of the other 403 
previously identified genes is retinoic acid signaling and metabolism61-63. ANO2 is a Ca2+-activated Cl- 404 
channel recently reported to regulate retinal pigment epithelial (RPE) cell volume in a light-dependent 405 
manner64. EDN2 is a potent vasoconstrictor that binds to two G-protein-coupled receptors, EDNRA, which 406 
resides on bipolar dendrites, and EDNRB, which is present on Mueller and horizontal cells. Both receptors 407 
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are also present on choroidal vessels65, implying that the choroid as well as retinal cells are target sites for 408 
this gene. RP1L1 is expressed in cone and rod photoreceptors where it is involved in the maintenance of 409 
microtubules in the connecting cilium66. Mutations in this gene cause dominant macular dystrophy and 410 
retinitis pigmentosa67. We replicated two genes known to cause myopia in family studies. FBN1 harbors 411 
mutations causing with Marfan (OMIM #154700) and Weil Marchesani (OMIM #608328) syndrome; 412 
PTPRR was one of the candidates in the MYP3 locus, which was found by linkage in families with high 413 
myopia68.  414 
 The location of rs7449443 (P value 3.58 x 10-8) is notable as it resides in between DRD1 and 415 
FLJ16171. DRD1 encodes dopamine receptor 1 and is known to modulate dopamine receptor 2-mediated 416 
events69,70. The dopamine pathway has been implicated in myopia pathogenesis in many studies69,71. SNPs 417 
in and near other genes involved in the dopamine pathway (dopamine receptors, synthesis, degradation, 418 
and transporters)72-74 did not reveal genome-wide significant associations (Supplementary Methods 2, 419 
Supplementary Table 8; Supplementary Figure 12). 420 
There were twenty-eight genetic variants in or near DNA structures transcribing RNA genes (non 421 
coding RNA, linc RNAs, tRNAs, snoRNas, rRNAs). Notably, five were in the transcription region and 422 
thirteen were in the vicinity ( >0 kb and ≤ 50 kb) of start or end of the RNA gene transcription region. 423 
They received low scores, since many have no reported function or disease association to date (Table 3, 424 
Supplementary Excel File 10, Supplementary Figure 11, Supplementary Table 7). Our ranking of genes 425 
based on functional information existing in the public domain does not necessarily represent the true 426 
order of importance for refractive error pathogenesis. The observation that genes with strong statistical 427 
association were distributed over all scores supports this concept. Nevertheless, this list may help to select 428 
genes for subsequent functional studies. 429 
Finally, integration of all aforementioned data with findings from literature allowed us to annotate 430 
a large number of genes to ocular cell types (Figure 6). Remarkably, all cell types of the retina harbored 431 
refractive error genes, as well as the RPE, vascular endothelium, and extracellular matrix.  432 
  433 
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Genetic pleiotropy  434 
We performed a GWAS catalogue look up using FUMA to investigate overlap of genes with other 435 
common traits (Supplementary Figure 13)75. Refractive error and hyperopia were replicated significantly 436 
after correcting for multiple testing (adjusted P value 1.44 x 10-52 and 9.34 x 10-9, respectively). We found 437 
significant overlap with 74 other traits, of which height (adjusted P value 1.11 x 10-10), obesity (adjusted 438 
P value 1.38 x 10-10), and BMI (adjusted P value 4.05 x 10-7) were most important. Ocular traits 439 
significantly associated were glaucoma (optic cup area, intraocular pressure; adjusted P values 2.69 x 10-5 440 
and 3.01 x 10-5, respectively) and age-related macular degeneration (adjusted P value 1.27 x 10-3). 441 
 442 
 443 
DISCUSSION 444 
Myopia may become the leading cause of world blindness in the near future, a grim outlook for which 445 
current counteractions are still insufficient11,76. To improve understanding of the genetic landscape and 446 
biology of the refractive error trait, we conducted a large GWAS meta-analysis in 160,420 participants of 447 
mixed ancestry and replicated in 95,505 participants. This led to the identification of 139 independent 448 
susceptibility loci by single variant analysis and 22 additional loci through post-GWAS methods, a four-449 
fold increase in refractive error genes. The majority of annotated genes were found to be expressed in the 450 
human posterior segment of the eye. Using in silico analysis, we identified significant biological 451 
pathways, of which retinal cell physiology, light processing, and specifically glutamate receptor signaling 452 
were the most prominent mechanisms. Our integrated bio-informatic approach highlighted known ocular 453 
functionality for many genes.  454 
  To ensure robustness of our genetic associations, we included studies of various designs and 455 
populations, sought replication in an independent cohort of significant sample size, and stringently 456 
accounted for population stratification by performing genomic control at all stages of the meta-analysis77. 457 
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With this approach, we internally replicated all loci from CREAM in 23andMe, and replicated a 458 
considerable proportion of the 23andMe loci in CREAM. We combined studies with outcomes based on 459 
actual refractive error measurements as well as on self-reported age-of-myopia-onset, and found the 460 
direction-of-effect of the associated variants, as well as their effect size, to be remarkably consistent. 461 
Combining two different outcome measures may appear unconventional, but age of onset and refractive 462 
error have been shown to be very tightly correlated11,28. Each year of earlier onset leads to a higher degree 463 
of myopia78,79. Moreover, the high genetic correlation of common SNPs between the two phenotypes 464 
underscores their similarity. Most compelling evidence was provided by replication of 86% of the 465 
discovered variants in the independent UKEV cohort which also used conventional refractive error 466 
measurements. This robustness indicates that both phenotypic outcomes (SphE and AODM) can be used 467 
to capture a shared source of genetic variation. In addition, we found trans-ethnic replication of 468 
significant loci, and a high per-allele correlation of genetic effects of common variants in the Europeans 469 
and Asians. Our findings support a largely shared genetic predisposition to refractive error and myopia in 470 
the two ethnicities, although ancestry-specific allelic effects may exist. The low heritability estimate in 471 
Asians may, in part, be explained by the low representation of this ethnicity in our study sample. 472 
Alternatively, it may imply that environmental factors explain a greater proportion of the phenotypic risk 473 
and recent rise in myopia prevalence in this ancestry group80.  474 
 Limitations of our study were the possibility of false negative findings due to genomic control, 475 
and underrepresentation of studies with Asian ancestry. Heterogeneity of observed effect estimates was 476 
large for several associated variants, but not unexpected given the large number of collaborating studies 477 
with varying methodology.  478 
 Although neurotransmission was already a suggested pathway in our previous studies26,27, our 479 
current pathway analyses provide more in depth insights into the retinal circuitry driving refractive error. 480 
DEPICT identified ‘thin retinal outer nuclear layer’, ‘detection of light stimulus’, and ‘nonmotile primary 481 
cilium’ as the most important meta-gene sets. These are the main characteristics of photoreceptors, which 482 
are located in the outer retina and contain cilia. These photosensitive cells drive the phototransduction 483 
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cascade in response to light, which in turn induces visual information processing. IPA pointed towards 484 
glutamate receptor signaling as the most significant pathway. Glutamate is released by photoreceptors and 485 
determines conductance of retinal signaling to the ON and OFF bipolar cells81. Our functional gene look 486 
ups provide evidence that rod as well as cone bipolar cells play a role (rod: CLU; cone: GNB3). Taken 487 
together, these findings strongly suggest that light response and light processing in the retina are initiating 488 
factors leading to refractive error. 489 
The genetic association with light dependent pathways may also link to the well-established 490 
protective effect of outdoor exposure on myopia. We found suggestive evidence for a genetic association 491 
with DRD1, the dopamine receptor D1 gene. The dopaminergic pathway has been studied extensively in 492 
animal models for its role in controlling eye growth in response to light69,71,82-91. DRD1 was found to be a 493 
mediator in this process, as bright light increased DRD1 activity in the bipolar ON-pathway, and 494 
diminished form deprivation myopia in mice. Blockage of DRD1 reversed this inhibitory effect92. We did 495 
not find evidence for direct involvement of other genes in the dopamine pathway, but GNB3 may be an 496 
indirect modifier as it is a downstream signaling molecule of dopamine and has been shown to influence 497 
availability of the dopamine transporter DAT93. Although a promising target for therapy, further evidence 498 
of DRD1 in human myopiagenesis is warranted.  499 
Novel pathways elicited by the newly identified genes are anterior segment morphology 500 
(TCF7L2, VIPR2, MAF) and angiogenesis (FLT1). In addition, the high number of variants residing near 501 
small RNA genes suggests that post-transcriptional regulation is an important mechanism, as these RNAs 502 
are known to play a distinct and central regulatory role in cells94. These findings will serve as leads for 503 
future studies performing detailed mapping of cellular networks, and functional studies into genes 504 
implicated in ocular phenotypes, harboring protein-altering variants, and proven drug targets.  505 
 Our evaluation of shared genetics between refractive error and other disease-relevant phenotypes 506 
highlighted overlap with anthropometric traits such as height, obesity, and BMI. This could give valuable 507 
additional clues as to the phenotypic outcomes of perturbations of some of the networks identified. 508 
20 
 
  Our genetic observations add credence to the current notion that refractive errors are caused by a 509 
retina-to-sclera signaling cascade that induces scleral remodeling in response to light stimuli. The concept 510 
of this cascade originates from various animal models showing that form deprivation, retinal defocus and 511 
contrast, ambient light, and wavelength can influence eye growth in young animals95-97. Cell-specific 512 
moieties in this putative signaling cascade in humans were largely unknown, although animal models 513 
implicated GABA, dopamine, all-trans-retinoic acid and TGF-β69,91,98,99. Our study provides a large 514 
number of new molecular candidates for this cascade, and clearly shows that a wide range of neuronal cell 515 
types in the retina, the RPE, the vascular endothelium, as well as components of the extracellular matrix 516 
are implicated (Figure 6). The many interprotein relationships (Figure 4) exemplify the complexity of eye 517 
growth, and provide a challenge to develop strategies to prevent pathological eye elongation.  518 
 In conclusion, by using a cross-ancestry design in the largest study population on common 519 
refractive errors to date, we uncovered numerous novel loci and pathways involved in eye growth. Our 520 
multi-disciplinary approach incorporating GWAS data with in silico analyses and expression experiments 521 
provides an example for the design of future genetic studies for complex traits. Additional genetic insights 522 
into refractive errors will be gained by increasing sample size, greater genotyping depth, family studies 523 
for identifying rare alleles of large effect, and by evaluating population extremes. Our list of plausible 524 
genes and pathways provide a plethora of data for future studies focusing on gene-environment 525 
interaction, and on translation of GWAS findings into starting points for therapy.  526 
 527 
  528 
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ONLINE METHODS 529 
Ethics Statement 530 
All human research was approved by the relevant institutional review boards and conducted according to 531 
the Declaration of Helsinki. All CREAM participants provided written informed consent; all 23andMe 532 
applicants provided informed consent online, and answered surveys according to 23andMe’s human 533 
subjects protocol, which was reviewed and approved by Ethical & Independent Review Services, an 534 
AAHRPP-accredited institutional review board. 535 
Study data 536 
The study populations were participants of the Consortium for Refractive Error and Myopia (CREAM) 537 
comprising of 41,793 individuals with European ancestry from 26 cohorts (CREAM-EUR) and 11,935 538 
individuals with Asian ancestry from 8 studies (CREAM-ASN); and customers of the 23andMe genetic 539 
testing company who gave informed consent for inclusion in research studies consisting of 104,293 540 
individuals (2 cohorts of individuals with European ancestry, N = 12,128 and N= 92,165, respectively). 541 
All participants included in this analysis from CREAM and 23andMe were aged 25 years or older. 542 
Participants with conditions that could alter refraction, such as cataract surgery, laser 543 
refractive procedures, retinal detachment surgery, keratoconus as well as ocular or systemic syndromes 544 
were excluded from the analyses. Recruitment and ascertainment strategies varied per study 545 
(Supplementary Table 1a,b, and Supplementary Methods 3). Refractive error represented by 546 
measurements of refraction and analyzed as spherical equivalent (SphE =spherical refractive error + 1/2 547 
cylinder refractive error) was the outcome variable for CREAM; myopic refractive error represented by 548 
self-reported age of diagnosis of myopia (AODM) for 23andMe27. 549 
  550 
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Genotype calling and imputation 551 
Samples were genotyped on different platforms and study specific quality control measures of the 552 
genotyped variants were implemented before association analysis (Supplementary Table 1a). Genotypes 553 
were imputed using the appropriate ancestry-matched reference panel for all cohorts from the 1000 554 
Genomes Project (Phase I version 3, March 2012 release) with either minimac100 or IMPUTE101,102. The 555 
metrics for pre-imputation quality control varied amongst studies, but genotype call rate thresholds were 556 
set at high level (≥0.95 for both CREAM and 23andMe). These metrics were similar to our previous 557 
GWAS analyses26,27; details per cohort can be found in Supplementary Table 1a. 558 
GWAS per study  559 
For each CREAM cohort, a single marker analysis for the SphE (in diopters) phenotype was carried out 560 
using linear regression adjusting for age, sex and up to the first five principal components. All non-561 
family-based cohorts removed one of each pair of relatives (after detection using either GCTA or 562 
IBS/IBD analysis). In family-based cohorts, a score test-based association was used to adjust for within-563 
family relatedness103,104. For the 23andMe participants, Cox proportional hazards analysis testing AODM 564 
as the dependent variable were performed as previously described27, with P values calculated using a 565 
likelihood ratio test for the single marker genotype term. We used an additive SNP allelic effect model for 566 
all analyses.  567 
 568 
Centralized quality control per study 569 
After individual GWAS, all studies underwent a second round of quality control (QC). Quantile-quantile, 570 
effect allele frequency, P – Z test, standard error – sample size, and genomic control inflation factor plots 571 
were generated for each individual cohort using EasyQC105 (Supplementary Figure 2.1, 2.2, 2.3) . All 572 
analytical issues discovered during this QC step were resolved per individual cohort. 573 
 574 
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GWAS meta-analyses 575 
The GWAS meta-analyses were performed in three stages (Supplementary Figure 1). In Stage 1, 576 
European (CREAM-EUR) and Asian (CREAM-ASN) participants from the CREAM cohort were meta-577 
analysed separately. Subsequently, all CREAM cohorts (CREAM-ALL) were meta-analysed. Variants 578 
with MAF < 1% or imputation quality score < 0.3 (info metric of IMPUTE) or Rsq < 0.3 (minimac) were 579 
excluded. A fixed effects inverse variance-weighted meta-analysis was performed using METAL106. In all 580 
stages, each genetic variant had to be represented by at least half of the entire study population and at 581 
least represented by 13 cohorts in CREAM and one cohort in 23andMe. For SNPs with high 582 
heterogeneity (at P < 0.05), we also performed a random effects meta-analysis using METASOFT50. In 583 
Stage 2, a meta-analysis of the two 23andMe cohorts was performed, using similar filtering but a lower 584 
MAF threshold (< 0.5%). In Stage 3, CREAM-ALL and 23andMe samples were combined using a fixed 585 
effects meta-analysis based on P values and direction of effect.  586 
In Stage 3, we chose a different weighting scheme due to the differences in effect size scaling; 23andMe 587 
used a less accurate phenotype variable (AODM); i.e. the effective sample size of the 23andMe was 588 
approximately equivalent to the effective sample size of CREAM-ALL (Figure 2b), thus weighting by 589 
(1/neffective) yielded a final weighting ratio of 1:1107,108. Genome-wide statistical significance was defined 590 
at P < 5.0 × 10-8 109. All three meta-analysis stages were performed under genomic control. Study specific 591 
and meta-analysis lambda (λ) estimates are shown in Supplementary Figure 7; to check for confounding 592 
biases (e.g. cryptic relatedness and population stratification), LD score intercepts from LD score 593 
regressions per ancestry were constructed (Supplementary Figure 8)30. To check the robustness of signals, 594 
we performed a conventional random effects models using METASOFT, fixed effects models weighted 595 
on sample size and on weights estimated from standard error per allele tested using METAL 596 
(Supplementary Excel Files 1 and Supplementary Excel Files 2). 597 
Manhattan (modified version of package ‘qqman’), regional, box, and forest plots were made using R 598 
version 3.2.3 and LocusZoom110. An overview of the Hardy Weinberg P values of all index variants per 599 
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cohort can be found in Supplementary Excel File 3. The comparison between refractive error and age-of-600 
onset was performed using the LDSC program30.  601 
 602 
Population stratification and heritability calculations 603 
Each study assessed the degree of genetic admixture and stratification in their study participants through 604 
the use of principal components. Homogeneity of participants was assured by removal of all individuals 605 
whose ancestry did not match the prevailing ancestral group. We used genomic inflation factors to control 606 
for admixture and stratification, and performed genomic-controlled meta-analysis to account for the 607 
effects of any residual heterogeneity. To further distinguish between inflation from a true polygenic signal 608 
and population stratification, we examined the relationship between test statistics and linkage 609 
disequilibrium (LD) with LDSC. CREAM-EUR, CREAM-ASN and 23andMe were evaluated separately; 610 
variants not present in HapMap3 and MAF < 1% were excluded. SNP heritability estimates were 611 
calculated using LDSC for the same set of genetic variants. 612 
Locus definition and annotation 613 
All study effect size estimates were oriented to the positive strand of the NCBI Build 37 reference 614 
sequence of the human genome. The index variant of a locus was defined as the variant with the lowest P 615 
value in a region spanning a 100 kb window of the most outer genome wide significant variant of that 616 
same region. We annotated all index variants using the web-based version of ANNOVAR111based on 617 
UCSC Known Gene Database35. For variants within the coding sequence or 5’ or 3’ untranslated regions 618 
of a gene, that gene was assigned to the index variant (note that this led to more than 1 gene being 619 
assigned to variants located within the transcription units of multiple, overlapping genes). For variants in 620 
intergenic regions, the nearest 5’ gene and the nearest 3’ gene were assigned to the variant. Index variants 621 
were annotated to functional RNA elements when described as such in the UCSC Known Gene Database. 622 
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We used conservation (PhyloP112) and prediction tools (SIFT39, Mutation Taster113, align GVGD40,41, 623 
PolyPhen-236) to predict the pathogenicity of protein-altering exonic variants.  624 
 625 
Conditional signal analysis 626 
 627 
We performed conditional analysis to identify additional independent signals nearby the index variant at 628 
each locus, using GCTA-COJO32. We transformed the Z-scores of the summary statistics to beta’s using 629 
the following formula: Standard Error = √1/2 ∗ 𝑁 ∗ 𝑀𝐴𝐹(1 − 𝑀𝐴𝐹) . We performed the GCTA-COJO 630 
analysis32, utilizing summary-level statistics from the meta-analysis on all cohorts. Linkage 631 
disequilibrium (LD) between variants was estimated from the Rotterdam Study I-III.  632 
 633 
Replication in UK Biobank  634 
The UK Biobank Eye & Vision (UKEV) Consortium performed a GWAS of refractive error in 95,505 635 
participants of European ancestry aged 37-73 year with no history of eye disorders33. Refractive error was 636 
measured using an autorefractor; SphE was calculated per eye and averaged between the two eyes. To 637 
account for relatedness a mixed model analysis with BOLT-LMM was used114, including age, gender, 638 
genotyping array, and the first 10 principal components as covariates. Analysis was restricted to markers 639 
present on the HRC reference panel115. We performed lookups for all independent genetic variants 640 
identified in our Stage 3 meta-analysis and conditional analysis. For variants not present in UKEV, we 641 
performed lookups for a surrogate variant in high LD (r2 >0.8). When more than one potential surrogate 642 
variant was available, the variant in strongest LD with the index variant was selected.  643 
 644 
Post-GWAS analyses  645 
We performed two gene-based tests to identify additional significant genes not found in the single variant 646 
analysis. First, we applied the gene-based test implemented in fastBAT42 to the per-variant summary 647 
statistics of the meta-analysis of all European cohorts (23andMe and CREAM-EUR). We used the default 648 
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parameters (all variants in or within 50kb of a gene) and focused on variants with a gene-based P value 649 
<2 x 10-6 (Bonferroni correction based on 25,000 genes) and the per-variant P value >5 x 10-8. Secondly, 650 
we applied another gene-based test in EUGENE43 which only includes variants which are eQTLs (GTex, 651 
blood116). EUGENE tests an hypothesis predicated on eQTLs as key drivers of the association signal. 652 
eQTLs within 50kb of a gene were included in the test. Genes with EUGENE P value <2 x 10-6 (and not 653 
found in the single variant analysis) were considered to be significant. Finally, we used functional 654 
annotation information from genome-wide significant loci to reweigh results using fgwas (version 655 
0.3.6444). This approach is able to identify risk loci that otherwise might not reach the genome-wide 656 
significance threshold in standard GWAS. Details about this approach can be found in Supplementary 657 
Methods 4.  658 
 659 
Refractive errors and myopia risk prediction 660 
To assess the risk of the entire range of refractive errors, we computed polygenic risk scores (PGRS) for 661 
the population-based Rotterdam Studies (RS) I, RS-II and RS-III using the P values and Z scores from a 662 
meta-analysis on CREAM-ALL and 23andMe, excluding the RS I-III cohorts. Only variants with high 663 
imputation quality (IMPUTE info score > 0.5 or minimac Rsq > 0.8) and MAF > 1% were considered. P 664 
value-based clumping was performed with PLINK117, using an r2 threshold of 0.2 and a physical distance 665 
threshold of 500 kb, excluding the MHC region. This resulted in a total of 243,938 variants. For each 666 
individual in RS-I, RS-II and RS-III (N = 10,792), PGRS were calculated using the --score command in 667 
PLINK across strata of P value thresholds: 5.0 x 10-8, 5.0 x 10-7, 5.0 x 10-6, 5.0 x 10-5, 5.0 x 10-4, 0.005, 668 
0.01, 0.05, 0.1, 0.5, 0.8 and 1.0. The proportion of variance explained by each PGRS model was 669 
calculated as the difference in the R2 between two regression models; one where SphE was regressed on 670 
age, sex, the first five principal components, and the other also including the PGRS as an additional 671 
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covariate. Subsequently, AUCs were calculated for myopia (SphE ≤ -3 SD) versus hyperopia (SphE ≥ +3 672 
SD). 673 
 674 
Genetic correlation between ancestries 675 
We used Popcorn48 to investigate ancestry-related differences in the genetic architecture of refractive 676 
error and myopia. Pairwise analyses were carried out using the GWAS summary statistics from 23andMe 677 
(N = 104,292), CREAM-EUR (N = 44,192) and CREAM-EAS (N = 9,826) meta-analyses. Only SNPs 678 
with MAF ≥ 5% were included, resulting in a final set of 3,625,602 SNPs for analyses involving 679 
23andMe and 3,642,928 SNPs for the CREAM-EUR versus CREAM-EAS analysis. Reference panels 680 
were constructed using genotype data from 503 European and 504 East Asian individuals sequenced as 681 
part of the 1000 Genomes Project (release 2013-05-02 downloaded from: ftp.1000genomes.ebi.ac.uk). 682 
The reference panel VCF files were filtered using PLINK117 to remove indels, strand-ambiguous variants, 683 
variants without an “rs” id prefix, and variants located in the MHC region on chromosome 6 684 
(chr6:25,000,000-33,500,000; Build 37). 685 
  686 
Analysis between phenotypes 687 
To evaluate consistency of genotypic effects across studies that employed different phenotype definitions, 688 
we compared effect sizes from GWAS studies of either SphE or AODM in Europeans, i.e. CREAM-EUR 689 
(N = 44,192) or 23andMe (N = 104,293) respectively. Marker-wise additive genetic effect sizes (in units 690 
diopters per copy of the risk allele) for SphE were compared against those (in units log(HR) per copy of 691 
the risk allele) for AODM. Data was visualised using R. Genetic correlation between the two phenotypes 692 
SphE and AODM was calculated using LD score regression. This analysis included all common SNPs 693 
(MAF > 0.01) present in HapMap3. 694 
 695 
Evidence for functional involvement 696 
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In order to rank genes according to biological plausibility, we scored annotated genes based on our own 697 
findings and published reports for a potential functional role in refractive error. Points were assigned for 698 
each gene on the basis of 10 categories (details on the methodology per category are provided in 699 
Supplementary Methods 3): internal replication of index genetic variants in the individual cohort GWAS 700 
analyses through Bonferroni corrections (CREAM-ASN, CREAM-EUR and 23andMe; pBonferroni 1.10 701 
x 10-4), evidence for eQTL using the FUMA32 and extensive look-ups in GtEx, evidence of expression in 702 
the eye in developmental and adult ocular tissues, presence of an eye phenotype in knock-out mice (MGI 703 
and IMPC database), presence of an eye phenotype in humans (OMIM118 (http://omim.org), 704 
DisGeNET119), location in a functional region of a gene (wANNOVAR), presence of the gene in a 705 
significant enriched functional pathway with false discovery rate < 0.05 (DEPICT49), presence of the gene 706 
in the gene priority analysis of DEPICT with false discovery rate < 0.05 and the presence of the gene in 707 
the canonical pathway analysis of Ingenuity Pathway Analysis (IPA; 708 
http://www.ingenuity.com/index.html). Furthermore, we performed a systematic search for each gene to 709 
assess its potential as a drug target (SuperTarget120, STITCH121, DrugBank122, PharmaGkb123). All 710 
information derived from this study and literature were used to annotate genes to retinal cell types. 711 
 712 
Genetic pleiotropy  713 
To investigate overlap of genes with other common traits, we performed a look-up in the GWAS catalog 714 
using FUMA. Multiple testing correction (i.e. Benjamini-Hochberg) was performed. Traits were 715 
significantly associated when adjusted P value ≤ 0.05 and the number of genes that overlap with the 716 
GWAS catalog gene sets was ≥ 2.  717 
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Figure 1. GWAS meta-analysis identifies 140 loci for refractive error (Stage 3) 1012 
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(a) We conducted a meta-analysis of genome-wide single-variant analyses for >10 million variants in 1030 
160,420 participants of CREAM and 23andMe (Stage 3). Shown is the Manhattan plot depicting P values 1031 
for association, highlighting new (P < 5 × 10−8 for the first time; green) and known (dark grey) refractive 1032 
error loci previously found using HapMap II imputations from Kiefer et al.27 and Verhoeven et al.26 1033 
(Table 1). The horizontal lines indicate suggestive significance (P = 1 × 10−5) or genome-wide 1034 
38 
 
significance (P = 5 × 10−8). (b) We compared the minor allele frequencies of the 140 discovered index 1035 
variants based on 1000G (blue: Europeans; red: Asians) to the minor allele frequencies of the previously 1036 
found genetic variants based on HapMap II (green: Europeans; purple: Asians). Observed are an increase 1037 
in genetic variants found across all minor allele frequency bins increase, including the lower minor allele 1038 
frequency bins. (c) We annotated the 167 loci to genes using wANNOVAR. Shown are the distances 1039 
between index variants from the nearest gene and its gene on the 5’ and/or 3’ site. The majority of index 1040 
variants (84%) were at a distance of less than 50 kb up- or downstream from the annotated gene.  1041 
 1042 
 1043 
1 
 
 1044 
Table 1. Results of the meta-analysis of CREAM and 23andMe for the previously-identified loci and a subset of the newly-identified loci, 1045 
and replication in UK Biobank 1046 
 1047 
 1048 
Table 1a Replication of the HapMap II index variants for refractive error per locus in the Stage 3 meta-analysis
SNP Chr. Position Nearest Loci And Gene(s) Effect 
Allele
Other 
Allele
 EAF 
EUR 
 EAF 
ASN 
Z-score Direction       P value HetISq  HetPVal Sample 
Size (N)
HapMap II Discovery (2013) Category (I = both GWS in Stage 1 and 2, 
2=one of two cohorts (CREAM or 23andMe) 
GWS, 3= both not GWS in Stage 1 or 2) 
P value Replication UKBB
rs10500355 16 7459347 RBFOX1 A T 0.354 0.1334 -13.73 -- 6.49E-43 9.1 2.93E-07 160139 Kiefer et a l . & Verhoeven et a l . I 2.50E-48
rs11145465 9 71766593 TJP2 A C 0.212 NA -9.55 -- 1.35E-21 46.3 0.1722 153174 Kiefer et a l . & Verhoeven et a l . I 1.00E-10
rs11178469 12 71275137 PTPRR T C 0.752 0.6384 -7.40 -- 1.33E-13 0 0.6989 160139 Verhoeven et a l . II (CREAM) 2.60E-04
rs11602008 11 40149305 LRRC4C A T 0.822 0.7488 13.98 ++ 2.12E-44 22.5 1.56E-10 157505 Kiefer et a l . II (23andMe) 2.90E-47
rs12193446 6 129820038 BC035400, LAMA2 A G 0.906 NA -19.43 -- 4.21E-84 16.8 5.72E-15 150269 Kiefer et a l . & Verhoeven et a l . I 4.60E-106
rs1550094 2 233385396 CHRNG,PRSS56 A G 0.701 0.705 12.74 ++ 3.64E-37 26.3 0.002705 159422
Kiefer et a l . & Verhoeven et a l ., 
Kiefer et a l . I 4.10E-59
rs1649068 10 60304864 BICC1 A C 0.475 0.5044 -9.44 -- 3.77E-21 0 0.7118 160144 Verhoeven et a l . I 7.50E-11
rs17382981 10 94953258 CYP26A1,MYOF T C 0.417 0.1901 -6.31 -- 2.72E-10 67.9 0.07737 155332 Verhoeven et a l . II (CREAM) 4.10E-07
rs17428076 2 172851936 HAT1,METAP1D C G 0.768 0.8542 -8.18 -- 2.77E-16 0 0.002854 160151 Kiefer et a l . II (23andMe) 7.50E-08
rs1858001 1 207488004 C4BPA,CD55 C G 0.676 0.4151 7.28 ++ 3.45E-13 59.6 0.02007 160149 Verhoeven et a l . II (CREAM) 6.70E-20
rs1954761 11 105596885 GRIA4 T C 0.371 0.3772 -8.40 -- 4.57E-17 0 0.911 160122 Verhoeven et a l . I 1.20E-16
rs2155413 11 84634790 DLG2 A C 0.482 0.6549 -7.76 -- 8.85E-15 0 0.0002987 159504 Kiefer et a l . II (23andMe) 1.10E-17
rs235770 20 6761765 BMP2 T C 0.372 0.3875 -5.93 -- 3.11E-09 0 0.5474 157521 Verhoeven et a l . II (23andMe) 4.80E-11
rs2573081 2 178828507 PDE11A C G 0.524 0.5378 8.21 ++ 2.18E-16 47.6 0.1672 160126 Kiefer et a l . II (23andMe) 1.60E-29
rs2753462 14 60850703 JB175233,C14orf39 C G 0.296 0.5679 -6.49 -- 8.37E-11 73.9 0.05032 157352 Verhoeven et a l . II (CREAM) 2.00E-15
rs2855530 14 54421917 BMP4 C G 0.507 0.4736 -8.58 -- 9.87E-18 41.7 0.1904 160092 Kiefer et a l . I 4.80E-22
rs2908972 17 11407259 SHISA6 A T 0.415 0.4879 -11.13 -- 9.46E-29 23 0.2544 160123 Kiefer et a l . & Verhoeven et a l . I 6.10E-29
rs3138141 12 56115778 BLOC1S1-RDH5,RDH5 A C 0.214 0.1472 13.80 ++ 2.46E-43 3.2 5.05E-07 157531 Kiefer et a l . & Verhoeven et a l . I 2.30E-56
rs4687586 3 53837971 CACNA1D C G 0.691 NA -6.55 -- 5.86E-11 0 0.6046 150217 Verhoeven et a l . III 1.60E-08
rs4793501 17 68718734 KCNJ2,BC039327 T C 0.575 0.444 -7.21 -- 5.53E-13 0 0.5917 160150 Verhoeven et a l . II (CREAM) 3.70E-12
rs524952 15 35005886 GOLGA8B,GJD2 A T 0.475 0.5077 -17.08 -- 2.28E-65 67.2 0.01544 160150 Kiefer et a l . & Verhoeven et a l . I 1.60E-103
rs56075542 2 146882415 BC040861,PABPC1P2 T G 0.552 0.4726 -8.99 -- 2.39E-19 13.9 0.001284 159478 Kiefer et a l . II (23andMe) 1.30E-18
rs62070229 17 31227593 MYO1D,TMEM98 A G 0.807 0.8747 8.58 ++ 9.64E-18 0 0.4158 156570 Verhoeven et a l . I 1.30E-18
rs6495367 15 79375347 RASGRF1 A G 0.408 0.3988 -10.20 -- 1.95E-24 0 0.667 160144 Kiefer et a l . & Verhoeven et a l . I 7.20E-37
rs7042950 9 77149837 RORB A G 0.732 0.3924 6.80 ++ 1.07E-11 0 0.9122 160153 Verhoeven et a l . III 2.90E-18
rs72621438 8 60178580 SNORA51,CA8 C G 0.642 0.6089 -13.14 -- 2.03E-39 38.4 0.00559 160128 Kiefer et a l . & Verhoeven et a l . I 1.80E-49
rs745480 10 85986554 LRIT2,LRIT1 C G 0.511 0.4182 8.31 ++ 9.26E-17 67.3 0.0805 159504 Kiefer et a l . II (23andMe) 8.20E-18
rs7624084 3 141093285 ZBTB38 T C 0.568 0.6332 -8.81 -- 1.24E-18 18.5 0.01802 160151 Kiefer et a l . II (23andMe) 6.50E-17
rs7662551 4 80537638 LOC100506035,PCAT4 A G 0.723 0.5577 8.53 ++ 1.47E-17 19.4 0.2653 160147 Verhoeven et a l . I 6.00E-12
rs7692381 4 81903049 C4orf22,BMP3 A G 0.763 0.6308 9.40 ++ 5.55E-21 0 0.01253 160134 Kiefer et a l . I 7.50E-13
rs7744813 6 73643289 KCNQ5 A C 0.591 0.6017 -14.56 -- 5.43E-48 35 0.001132 160091 Kiefer et a l . & Verhoeven et a l . I 1.00E-75
rs7829127 8 40726394 ZMAT4 A G 0.792 0.8974 -10.91 -- 1.02E-27 15.9 0.0002774 160132 Kiefer et a l . & Verhoeven et a l . II (23andMe) 3.10E-22
rs7895108 10 79061458 KCNMA1 T G 0.351 0.1182 -8.87 -- 7.56E-19 32.8 0.02115 160140 Kiefer et a l . II (23andMe) 1.10E-27
rs79266634 16 7309047 RBFOX1 C G 0.093 0.1151 -5.93 -- 3.00E-09 0 0.5614 156268 Kiefer et a l . & Verhoeven et a l . III 1.50E-08
rs837323 13 101175664 PCCA T C 0.512 0.7625 6.32 ++ 2.65E-10 35.6 0.2129 160142 Verhoeven et a l . II (23andMe) 5.30E-16
rs9517964 13 100717833 ZIC2,PCCA T C 0.589 0.786 8.42 ++ 3.68E-17 0 0.01962 160121 Kiefer et a l . II (23andMe) 3.40E-20
Table 1b Subset of the new loci harboring the smallest p-values for refractive error in the Stage 3 meta-analysis
SNP Chr. Position Nearest Loci And Gene(s) Effect 
Allele
Other 
Allele
 EAF 
EUR 
 EAF 
ASN 
Z-score Direction       P value HetISq  HetPVal Sample 
Size (N)
Category (I = both GWS in Stage 1 and 2, 
2=one of two cohorts (CREAM or 23andMe) 
GWS, 3= not GWS in Stage 1 or 2) 
P value Replication UKBB
rs36024104 14 42294993 LRFN5 A G 0.823 NA 9.09 ++ 9.86E-20 15.9 0.01414 152585 II (23andMe) 2.20E-12
rs7456039 7 6901710 CCZ1B,LOC100131257 C G 0.183 NA 8.82 ++ 1.18E-18 42.1 3.79E-12 121337 II (23andMe) 6.50E-01
rs1556867 1 164213686 5S_rRNA,PBX1 T C 0.264 0.494 -8.81 -- 1.29E-18 71.1 0.06266 160155 II (23andMe) 4.20E-17
rs12667032 7 154406581 DPP6 A G 0.152 0.317 7.99 ++ 1.31E-15 82.3 1.02E-11 130790 II (23andMe) 2.10E-01
rs2225986 1 200311910 LINC00862 A T 0.381 0.169 -7.96 -- 1.68E-15 40.2 0.196 160152 II (23andMe) 7.50E-17
rs1207782 6 22059967 LINC00340 T C 0.577 0.265 -7.92 -- 2.47E-15 0 0.8946 160149 I 4.90E-13
rs72826094 10 114801488 TCF7L2 A T 0.799 0.838 7.88 ++ 3.20E-15 64.5 0.09323 156825 II (23andMe) 4.90E-02
rs297593 2 157363743 GPD2 T C 0.286 0.257 -7.82 -- 5.45E-15 0 0.5285 159461 II (23andMe) 7.80E-11
rs5442 12 6954864 GNB3 A G 0.068 NA -7.82 -- 5.48E-15 8.8 0.03693 146217 II (23andMe) 1.20E-33
rs10880855 12 46144855 ARID2 T C 0.507 0.464 -7.78 -- 7.35E-15 0 0.9683 160144 I 4.80E-08
rs12405776 1 242431557 PLD5 T C 0.220 0.521 7.75 ++ 9.52E-15 64.9 3.56E-10 153784 II (23andMe) 1.50E-01
rs2150458 21 47377296 PCBP3,COL6A1 A G 0.455 0.641 7.74 ++ 1.04E-14 55.7 0.1329 160151 II (23andMe) 1.80E-13
rs12898755 15 63574641 APH1B A G 0.245 0.456 7.53 ++ 4.98E-14 7.9 0.2974 159506 II (23andMe) 1.40E-16
rs7122817 11 117657679 DSCAML1 A G 0.507 0.662 7.51 ++ 5.73E-14 73.8 0.05077 160147 II (23andMe) 1.10E-10
rs10511652 9 18362865 SH3GL2,ADAMTSL1 A G 0.416 0.445 7.36 ++ 1.91E-13 44.8 0.1782 160149 II (23andMe) 3.50E-18
rs11101263 10 49414181 FRMPD2 T C 0.258 0.105 -7.33 -- 2.33E-13 0 0.3477 160155 II (23andMe) 2.20E-13
rs11118367 1 219790221 LYPLAL1 T C 0.482 0.630 -7.29 -- 3.16E-13 0 0.8576 160141 III 1.20E-13
rs9395623 6 50757699 TFAP2D,TFAP2B A T 0.315 0.381 7.25 ++ 4.16E-13 0 0.9579 160151 III 2.20E-10
rs284816 8 53362145 ST18,FAM150A A G 0.163 0.198 -7.21 -- 5.52E-13 0 0.9242 160140 III 1.60E-08
rs12965607 18 47391025 MYO5B T G 0.857 0.923 7.07 ++ 1.52E-12 20.8 0.01674 157604 II (23andMe) 8.10E-16
rs7747 4 80827062 ANTXR2 T C 0.202 0.093 7.03 ++ 2.05E-12 5.4 0.01267 150327 II (23andMe) 7.70E-16
rs12451582 17 54734643 NOG,C17orf67 A G 0.369 0.308 7.02 ++ 2.22E-12 0 0.5925 160155 II (23andMe) 8.80E-18
rs80253120 17 14138507 CDRT15 T C 0.626 0.723 6.97 ++ 3.25E-12 58.6 0.12 156054 II (23andMe) 7.20E-11
22:23069851:I 22 23069851 DKFZp667J0810,abParts ATG A 0.084 0.1582 6.95 -+ 3.56E-12 98.5 4.80E-16 120481 II (23andMe) 9.30E-01
rs7968679 12 9313304 PZP A G 0.700 0.894 6.95 ++ 3.65E-12 0 0.01951 160076 II (23andMe) 4.20E-10
rs11202736 10 90142203 RNLS A T 0.717 0.762 -6.92 -- 4.53E-12 0 0.4007 160150 II (23andMe) 9.40E-07
rs11088317 21 16574122 NRIP1,USP25 T C 0.287 0.299 -6.90 -- 5.38E-12 72.5 0.05657 160116 II (23andMe) 6.50E-06
rs10853531 18 42824449 SLC14A2 A G 0.200 0.182 6.88 ++ 5.89E-12 0 0.6755 160104 III 2.60E-10
rs72655575 8 60556509 SNORA51,CA8 A C 0.201 0.124 6.87 ++ 6.54E-12 0 0.8811 156566 I 7.10E-07
rs12998513 2 242879499 CXXC11,AK097934 A G 0.880 0.676 -6.86 +- 7.15E-12 65.2 4.51E-14 117611 II (23andMe) 7.80E-01
rs1790165 11 131928971 NTM A C 0.411 0.283 6.85 ++ 7.17E-12 0 0.003708 160131 II (23andMe) 1.80E-10
rs511217 11 30029948 METTL15,KCNA4 A T 0.738 0.729 -6.79 -- 1.10E-11 0 0.3626 160143 II (23andMe) 1.40E-17
rs1150687 6 28162469 ZNF192P1,TRNA_Ser T C 0.619 0.504 6.78 ++ 1.17E-11 56.2 0.131 159448 II (23andMe) 3.10E-10
rs56055503 16 80532694 MAF,DYNLRB2 A G 0.751 0.539 -6.72 -- 1.83E-11 0 0.8407 160145 II (23andMe) 8.00E-06
rs9681162 3 8194734 AK124857,LMCD1-AS1 T C 0.680 0.437 6.70 ++ 2.10E-11 63 0.1002 160152 II (23andMe) 6.30E-13
rs11589487 1 61342229 AK097193,BC030753 A G 0.445 0.089 6.67 ++ 2.64E-11 34.6 0.2163 160143 II (23andMe) 2.20E-10
We identified 140 loci for refractive error with genome-wide significance (P < 5 × 10−8) on the basis the meta-analyses of the genome-wide single-variant linear regressions performed in 160,420 participants of mixed 
ancestries (CREAM-ASN, CREAM-EUR and 23andMe). Shown are the replication of the previously found loci from HapMap II and a subset of the new loci harboring the smallest p-values. For each locus, represented by 
an index variant (the variant with smallest p-value in that locus), Effect Allele, Other Allele, effect allele frequencies per ancestry (EAF AZN and EAF EUR), effect size (Z-score), direction of the effect (Direction), the P 
value, heterogeneity I square (HetISq), heterogeneity P value (HetPval), Sample Size (N), Category and P value of the replication in UK Biobank are shown (Full table: Supplementary Excel Table 1). Chr., chromosome; 
EAF, effect allele frequency; ASN, Asian; EUR, European; GWS, genome wide significant; UKBB, United Kingdom Biobank.
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Table 1a Replication of the HapMap II index variants for refractive error per locus in the Stage 3 meta-analysis
SNP Chr. Position Nearest Loci And Gene(s) Effect 
Allele
Other 
Allele
 EAF 
EUR 
 EAF 
ASN 
Z-score Direction       P value HetISq  HetPVal Sample 
Size (N)
HapMap II Discovery (2013) Category (I = both GWS in Stage 1 and 2, 
2=one of two cohorts (CREAM or 23andMe) 
GWS, 3= both not GWS in Stage 1 or 2) 
P value Replication UKBB
rs10500355 16 7459347 RBFOX1 A T 0.354 0.1334 -13.73 -- 6.49E-43 9.1 2.93E-07 160139 Kiefer et a l . & Verhoeven et a l . I 2.50E-48
rs11145465 9 71766593 TJP2 A C 0.212 NA -9.55 -- 1.35E-21 46.3 0.1722 153174 Kiefer et a l . & Verhoeven et a l . I 1.00E-10
rs11178469 12 71275137 PTPRR T C 0.752 0.6384 -7.40 -- 1.33E-13 0 0.6989 160139 Verhoeven et a l . II (CREAM) 2.60E-04
rs11602008 11 40149305 LRRC4C A T 0.822 0.7488 13.98 ++ 2.12E-44 22.5 1.56E-10 157505 Kiefer et a l . II (23andMe) 2.90E-47
rs12193446 6 129820038 BC035400, LAMA2 A G 0.906 NA -19.43 -- 4.21E-84 16.8 5.72E-15 150269 Kiefer et a l . & Verhoeven et a l . I 4.60E-106
rs1550094 2 233385396 CHRNG,PRSS56 A G 0.701 0.705 12.74 ++ 3.64E-37 26.3 0.002705 159422
Kiefer et a l . & Verhoeven et a l ., 
Kiefer et a l . I 4.10E-59
rs1649068 10 60304864 BICC1 A C 0.475 0.5044 -9.44 -- 3.77E-21 0 0.7118 160144 Verhoeven et a l . I 7.50E-11
rs17382981 10 94953258 CYP26A1,MYOF T C 0.417 0.1901 -6.31 -- 2.72E-10 67.9 0.07737 155332 Verhoeven et a l . II (CREAM) 4.10E-07
rs17428076 2 172851936 HAT1,METAP1D C G 0.768 0.8542 -8.18 -- 2.77E-16 0 0.002854 160151 Kiefer et a l . II (23andMe) 7.50E-08
rs1858001 1 207488004 C4BPA,CD55 C G 0.676 0.4151 7.28 ++ 3.45E-13 59.6 0.02007 160149 Verhoeven et a l . II (CREAM) 6.70E-20
rs1954761 11 105596885 GRIA4 T C 0.371 0.3772 -8.40 -- 4.57E-17 0 0.911 160122 Verhoeven et a l . I 1.20E-16
rs2155413 11 84634790 DLG2 A C 0.482 0.6549 -7.76 -- 8.85E-15 0 0.0002987 159504 Kiefer et a l . II (23andMe) 1.10E-17
rs235770 20 6761765 BMP2 T C 0.372 0.3875 -5.93 -- 3.11E-09 0 0.5474 157521 Verhoeven et a l . II (23andMe) 4.80E-11
rs2573081 2 178828507 PDE11A C G 0.524 0.5378 8.21 ++ 2.18E-16 47.6 0.1672 160126 Kiefer et a l . II (23andMe) 1.60E-29
rs2753462 14 60850703 JB175233,C14orf39 C G 0.296 0.5679 -6.49 -- 8.37E-11 73.9 0.05032 157352 Verhoeven et a l . II (CREAM) 2.00E-15
rs2855530 14 54421917 BMP4 C G 0.507 0.4736 -8.58 -- 9.87E-18 41.7 0.1904 160092 Kiefer et a l . I 4.80E-22
rs2908972 17 11407259 SHISA6 A T 0.415 0.4879 -11.13 -- 9.46E-29 23 0.2544 160123 Kiefer et a l . & Verhoeven et a l . I 6.10E-29
rs3138141 12 56115778 BLOC1S1-RDH5,RDH5 A C 0.214 0.1472 13.80 ++ 2.46E-43 3.2 5.05E-07 157531 Kiefer et a l . & Verhoeven et a l . I 2.30E-56
rs4687586 3 53837971 CACNA1D C G 0.691 NA -6.55 -- 5.86E-11 0 0.6046 150217 Verhoeven et a l . III 1.60E-08
rs4793501 17 68718734 KCNJ2,BC039327 T C 0.575 0.444 -7.21 -- 5.53E-13 0 0.5917 160150 Verhoeven et a l . II (CREAM) 3.70E-12
rs524952 15 35005886 GOLGA8B,GJD2 A T 0.475 0.5077 -17.08 -- 2.28E-65 67.2 0.01544 160150 Kiefer et a l . & Verhoeven et a l . I 1.60E-103
rs56075542 2 146882415 BC040861,PABPC1P2 T G 0.552 0.4726 -8.99 -- 2.39E-19 13.9 0.001284 159478 Kiefer et a l . II (23andMe) 1.30E-18
rs62070229 17 31227593 MYO1D,TMEM98 A G 0.807 0.8747 8.58 ++ 9.64E-18 0 0.4158 156570 Verhoeven et a l . I 1.30E-18
rs6495367 15 79375347 RASGRF1 A G 0.408 0.3988 -10.20 -- 1.95E-24 0 0.667 160144 Kiefer et a l . & Verhoeven et a l . I 7.20E-37
rs7042950 9 77149837 RORB A G 0.732 0.3924 6.80 ++ 1.07E-11 0 0.9122 160153 Verhoeven et a l . III 2.90E-18
rs72621438 8 60178580 SNORA51,CA8 C G 0.642 0.6089 -13.14 -- 2.03E-39 38.4 0.00559 160128 Kiefer et a l . & Verhoeven et a l . I 1.80E-49
rs745480 10 85986554 LRIT2,LRIT1 C G 0.511 0.4182 8.31 ++ 9.26E-17 67.3 0.0805 159504 Kiefer et a l . II (23andMe) 8.20E-18
rs7624084 3 141093285 ZBTB38 T C 0.568 0.6332 -8.81 -- 1.24E-18 18.5 0.01802 160151 Kiefer et a l . II (23andMe) 6.50E-17
rs7662551 4 80537638 LOC100506035,PCAT4 A G 0.723 0.5577 8.53 ++ 1.47E-17 19.4 0.2653 160147 Verhoeven et a l . I 6.00E-12
rs7692381 4 81903049 C4orf22,BMP3 A G 0.763 0.6308 9.40 ++ 5.55E-21 0 0.01253 160134 Kiefer et a l . I 7.50E-13
rs7744813 6 73643289 KCNQ5 A C 0.591 0.6017 -14.56 -- 5.43E-48 35 0.001132 160091 Kiefer et a l . & Verhoeven et a l . I 1.00E-75
rs7829127 8 40726394 ZMAT4 A G 0.792 0.8974 -10.91 -- 1.02E-27 15.9 0.0002774 160132 Kiefer et a l . & Verhoeven et a l . II (23andMe) 3.10E-22
rs7895108 10 79061458 KCNMA1 T G 0.351 0.1182 -8.87 -- 7.56E-19 32.8 0.02115 160140 Kiefer et a l . II (23andMe) 1.10E-27
rs79266634 16 7309047 RBFOX1 C G 0.093 0.1151 -5.93 -- 3.00E-09 0 0.5614 156268 Kiefer et a l . & Verhoeven et a l . III 1.50E-08
rs837323 13 101175664 PCCA T C 0.512 0.7625 6.32 ++ 2.65E-10 35.6 0.2129 160142 Verhoeven et a l . II (23andMe) 5.30E-16
rs9517964 13 100717833 ZIC2,PCCA T C 0.589 0.786 8.42 ++ 3.68E-17 0 0.01962 160121 Kiefer et a l . II (23andMe) 3.40E-20
Table 1b Subset of the new loci harboring the smallest p-values for refractive error in the Stage 3 meta-analysis
SNP Chr. Position Nearest Loci And Gene(s) Effect 
Allele
Other 
Allele
 EAF 
EUR 
 EAF 
ASN 
Z-score Direction       P value HetISq  HetPVal Sample 
Size (N)
Category (I = both GWS in Stage 1 and 2, 
2=one of two cohorts (CREAM or 23andMe) 
GWS, 3= not GWS in Stage 1 or 2) 
P value Replication UKBB
rs36024104 14 42294993 LRFN5 A G 0.823 NA 9.09 ++ 9.86E-20 15.9 0.01414 152585 II (23andMe) 2.20E-12
rs7456039 7 6901710 CCZ1B,LOC100131257 C G 0.183 NA 8.82 ++ 1.18E-18 42.1 3.79E-12 121337 II (23andMe) 6.50E-01
rs1556867 1 164213686 5S_rRNA,PBX1 T C 0.264 0.494 -8.81 -- 1.29E-18 71.1 0.06266 160155 II (23andMe) 4.20E-17
rs12667032 7 154406581 DPP6 A G 0.152 0.317 7.99 ++ 1.31E-15 82.3 1.02E-11 130790 II (23andMe) 2.10E-01
rs2225986 1 200311910 LINC00862 A T 0.381 0.169 -7.96 -- 1.68E-15 40.2 0.196 160152 II (23andMe) 7.50E-17
rs1207782 6 22059967 LINC00340 T C 0.577 0.265 -7.92 -- 2.47E-15 0 0.8946 160149 I 4.90E-13
rs72826094 10 114801488 TCF7L2 A T 0.799 0.838 7.88 ++ 3.20E-15 64.5 0.09323 156825 II (23andMe) 4.90E-02
rs297593 2 157363743 GPD2 T C 0.286 0.257 -7.82 -- 5.45E-15 0 0.5285 159461 II (23andMe) 7.80E-11
rs5442 12 6954864 GNB3 A G 0.068 NA -7.82 -- 5.48E-15 8.8 0.03693 146217 II (23andMe) 1.20E-33
rs10880855 12 46144855 ARID2 T C 0.507 0.464 -7.78 -- 7.35E-15 0 0.9683 160144 I 4.80E-08
rs12405776 1 242431557 PLD5 T C 0.220 0.521 7.75 ++ 9.52E-15 64.9 3.56E-10 153784 II (23andMe) 1.50E-01
rs2150458 21 47377296 PCBP3,COL6A1 A G 0.455 0.641 7.74 ++ 1.04E-14 55.7 0.1329 160151 II (23andMe) 1.80E-13
rs12898755 15 63574641 APH1B A G 0.245 0.456 7.53 ++ 4.98E-14 7.9 0.2974 159506 II (23andMe) 1.40E-16
rs7122817 11 117657679 DSCAML1 A G 0.507 0.662 7.51 ++ 5.73E-14 73.8 0.05077 160147 II (23andMe) 1.10E-10
rs10511652 9 18362865 SH3GL2,ADAMTSL1 A G 0.416 0.445 7.36 ++ 1.91E-13 44.8 0.1782 160149 II (23andMe) 3.50E-18
rs11101263 10 49414181 FRMPD2 T C 0.258 0.105 -7.33 -- 2.33E-13 0 0.3477 160155 II (23andMe) 2.20E-13
rs11118367 1 219790221 LYPLAL1 T C 0.482 0.630 -7.29 -- 3.16E-13 0 0.8576 160141 III 1.20E-13
rs9395623 6 50757699 TFAP2D,TFAP2B A T 0.315 0.381 7.25 ++ 4.16E-13 0 0.9579 160151 III 2.20E-10
rs284816 8 53362145 ST18,FAM150A A G 0.163 0.198 -7.21 -- 5.52E-13 0 0.9242 160140 III 1.60E-08
rs12965607 18 47391025 MYO5B T G 0.857 0.923 7.07 ++ 1.52E-12 20.8 0.01674 157604 II (23andMe) 8.10E-16
rs7747 4 80827062 ANTXR2 T C 0.202 0.093 7.03 ++ 2.05E-12 5.4 0.01267 150327 II (23andMe) 7.70E-16
rs12451582 17 54734643 NOG,C17orf67 A G 0.369 0.308 7.02 ++ 2.22E-12 0 0.5925 160155 II (23andMe) 8.80E-18
rs80253120 17 14138507 CDRT15 T C 0.626 0.723 6.97 ++ 3.25E-12 58.6 0.12 156054 II (23andMe) 7.20E-11
22:23069851:I 22 23069851 DKFZp667J0810,abParts ATG A 0.084 0.1582 6.95 -+ 3.56E-12 98.5 4.80E-16 120481 II (23andMe) 9.30E-01
rs7968679 12 9313304 PZP A G 0.700 0.894 6.95 ++ 3.65E-12 0 0.01951 160076 II (23andMe) 4.20E-10
rs11202736 10 90142203 RNLS A T 0.717 0.762 -6.92 -- 4.53E-12 0 0.4007 160150 II (23andMe) 9.40E-07
rs11088317 21 16574122 NRIP1,USP25 T C 0.287 0.299 -6.90 -- 5.38E-12 72.5 0.05657 160116 II (23andMe) 6.50E-06
rs10853531 18 42824449 SLC14A2 A G 0.200 0.182 6.88 ++ 5.89E-12 0 0.6755 160104 III 2.60E-10
rs72655575 8 60556509 SNORA51,CA8 A C 0.201 0.124 6.87 ++ 6.54E-12 0 0.8811 156566 I 7.10E-07
rs12998513 2 242879499 CXXC11,AK097934 A G 0.880 0.676 -6.86 +- 7.15E-12 65.2 4.51E-14 117611 II (23andMe) 7.80E-01
rs1790165 11 131928971 NTM A C 0.411 0.283 6.85 ++ 7.17E-12 0 0.003708 160131 II (23andMe) 1.80E-10
rs511217 11 30029948 METTL15,KCNA4 A T 0.738 0.729 -6.79 -- 1.10E-11 0 0.3626 160143 II (23andMe) 1.40E-17
rs1150687 6 28162469 ZNF192P1,TRNA_Ser T C 0.619 0.504 6.78 ++ 1.17E-11 56.2 0.131 159448 II (23andMe) 3.10E-10
rs56055503 16 80532694 MAF,DYNLRB2 A G 0.751 0.539 -6.72 -- 1.83E-11 0 0.8407 160145 II (23andMe) 8.00E-06
rs9681162 3 8194734 AK124857,LMCD1-AS1 T C 0.680 0.437 6.70 ++ 2.10E-11 63 0.1002 160152 II (23andMe) 6.30E-13
rs11589487 1 61342229 AK097193,BC030753 A G 0.445 0.089 6.67 ++ 2.64E-11 34.6 0.2163 160143 II (23andMe) 2.20E-10
We identified 140 loci for refractive error with genome-wide significance (P < 5 × 10−8) on the basis the meta-analyses of the genome-wide single-variant linear regressions performed in 160,420 participants of mixed 
ancestries (CREAM-ASN, CREAM-EUR and 23andMe). Shown are the replication of the previously found loci from HapMap II and a subset of the new loci harboring the smallest p-values. For each locus, represented by 
an index variant (the variant with smallest p-value in that locus), Effect Allele, Other Allele, effect allele frequencies per ancestry (EAF AZN and EAF EUR), effect size (Z-score), direction of the effect (Direction), the P 
value, heterogeneity I square (HetISq), heterogeneity P value (HetPval), Sample Size (N), Category and P value of the replication in UK Biobank are shown (Full table: Supplementary Excel Table 1). Chr., chromosome; 
EAF, effect allele frequency; ASN, Asian; EUR, European; GWS, genome wide significant; UKBB, United Kingdom Biobank.
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 1053 
Figure 2. Correlation of statistical significance and effect size of SNPs based on spherical equivalent 1054 
(SphE) in diopters and age of diagnosis of myopia (AODM) in years.1055 
 1056 
 1057 
 (a) P value per genetic variant comparison between CREAM meta-analysis (Stage 1) and 23andMe 1058 
(Stage 2) meta-analysis. Shown is the overlap (red) and the difference (green) in P value signals per 1059 
cohort for genetic variants. Green genetic variants are only genome wide significant in either CREAM or 1060 
23andMe. Blue: genetic variants with P value between 5.0 x 10-8 and 1.0 x 10-3 in both CREAM and 1061 
23andMe. (b) Comparison of effects (SphE and logHR of AODM in years) between CREAM and 1062 
23andMe. Same color code was applied as in (a). The effects were concordant in their direction of effect 1063 
on refractive error. The regression slope is -0.15 diopters per logHR of AODM in years.1064 
B 
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Figure 3. Risk of refractive error per decile of polygenic risk score (Rotterdam Study I-III, N = 1065 
10,792) 1066 
 1067 
Distribution of refractive error in subjects from Rotterdam Study I–III (N = 10,792) as a function 1068 
of the optimal polygenic risk score (including 7,303 variants at P value ≤ 0.005 explaining 7.8% of the 1069 
variance of SphE; Supplementary Table 9). Mean OR of myopia (black line) was calculated per polygenic 1070 
risk score category using the lowest category as a reference. High myopia (SphE ≤-6 D), moderate 1071 
myopia (SphE >-6 D & ≤ −3 D), low myopia (SphE > −3 D & <-1.5 D), emmetropia (SphE ≥ −1.5 D and 1072 
≤ 1.5 D), low hyperopia (SphE > 1.5 D & < 3 D), moderate hyperopia (SphE ≥ 3 D & 6 D), high 1073 
hyperopia (SphE ≥ 6 D).  1074 
  1075 
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Table 1. Genetic correlation for refractive error between Europeans and East Asians 1076 
Sample 1 Sample 2 Genetic effect correlation (pge) 
a 
Genetic impact correlation (pgi) a 
EUR 
CREAM 
EAS 
CREAM 
0.804 (se=0.041) P = 1.83 x 10-6 0.888 (se=0.061) P = 0.065 
EUR 
23andMe  
EAS 
CREAM 
0.788 (se=0.041) P = 2.48 x 10-7 0.865 (se=0.054) P = 0.014 
Abbreviations: EUR, European; EAS, East Asian. 
a P-value relates to a test of the null hypothesis that pge=1 or pgi=1. 
 1077 
We calculated the genetic correlation of effect (pge) and impact (pgi) using Popcorn to compare the 1078 
genetic associations between Europeans (CREAM-EUR, N= 44,192; 23andMe, N=104,292) and East 1079 
Asians (CREAM-ASN, N= 9,826). Reference panels for Popcorn were constructed using genotype data 1080 
for 503 EUR and 504 EAS individuals sequenced as part of the 1000 Genomes Project. SNPs used had a 1081 
MAF of at least 5% in both populations, resulting in a final set of 3,625,602SNPs for the analyses using 1082 
the 23andMe GWAS sample and 3,642,928 SNPs for those using the CREAM-EUR sample. These 1083 
findings support a largely common genetic predisposition to refractive error and myopia in Europeans and 1084 
Asians, although ancestry-specific risk alleles may exist.  1085 
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Figure 4. Visualization of the DEPICT gene-set enrichment analysis based on loci associated with 1086 
refractive error and the correlation between the (meta)gene sets 1087 
 1088 
(a) Shown are the 66 gene sets clustered into thirteen meta gene sets based on the gene set enrichment 1089 
analysis of DEPICT (P value < 1 × 10−5 in the GWAS, FDR < 0.05). (b) Visualization of the 1090 
interconnectivity between gene sets (n=13) of the meta gene set ‘Detection of Light Stimulus’ 1091 
(GO:0009583). (c) Visualization of the interconnectivity between gene sets (n=27) of the largest meta 1092 
gene set ‘Thin Retinal Outer Nuclear Layer’ (MP:0008515). In all panels, (meta)gene sets are represented 1093 
by nodes colored according to statistical significance, and similarities between them are indicated by 1094 
edges scaled according to their correlation; r ≥ 0.2 are shown in panel (a) and r ≥ 0.4 are shown in panel 1095 
(b,c).1096 
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Table 2. Genes ranked according to biological and statistical evidence 1097 
 1098 
Genes were ranked (orange) based on 10 equal categories which can be divided in four categories: 1099 
internal replication of genetic variant in more than two cohorts (purple; CREAM-EUR, CREAM-ASN 1100 
and/or 23andMe), annotation (light blue; genetic variant harboring an exonic protein altering variant or 1101 
non-protein altering variant, genetic variant residing in a 5’ or 3’ UTR region of a gene or transcribing an 1102 
RNA structure), expression (yellow; eQTL, expression in adult human ocular tissue, expression in 1103 
developing ocular tissue), biology (dark yellow; ocular phenotype in mice, ocular phenotype in humans), 1104 
pathways (green; DEPICT gene-set enrichtment, DEPICT gene prioritization analysis and canonical 1105 
pathway analysis of IPA). We assessed genes harboring drug targets (salmon red), but did not assign a 1106 
scoring point to this category. 1107 
 1108 
*Only one point can be assigned in the category ‘ANNOTATION’, even though it has four columns (i.e. 1109 
a genetic variant is located in only 1 of these four categories). 1110 
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Figure 5. Top molecular network identified by Ingenuity Pathway Analysis (IPA)  1111 
 1112 
 1113 
The genes annotated to the top hits identified at Stage 3 were mapped to networks and pathways present 1114 
in the IPA database. The most significant network identified by Fisher’s exact test was ‘Glutamate 1115 
Receptor Signaling’ (P value= 1.56 x 10-4). Genes within the network indicated in grey are genes 1116 
associated with refractive error. Other significant pathways are depicted in Supplementary Figure 10. 1117 
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Figure 6. Schematic representation of the human eye, retinal cell types, and functional sites of associated genes  1118 
 1119 
We assessed gene expression sites and/or functional target cells in the eye for all genes using our expression data and literature and data present in 1120 
the public domain. The genes appear to be distributed across virtually all cell types in the neurosensory retina, in the RPE, vascular endothelium 1121 
and extracellular matrix; i.e., the route of the myopic retina-to-sclera signalling cascade. 1122 
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